Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes - Huang, Can; Ding, Yufang; Chen, Zhen; Wu, Lijun; Wei, Wei; Zhao, Cheng; Yang, Min; Lin, Shudian; Wang, Qian; Tian, Xinping; Zhao, Jiuliang; Li, Mengtao; et al. (BMC medicine, 2025)
Keywords: Adult; Antibodies; Antibodies, Antiphospholipid - blood; Anticoagulants; Antiphospholipid antibodies; Antiphospholipid antibodies (aPLs); Antiphospholipid syndrome (APS); Arteriosclerosis; Arthritis; Aspirin; Asymptomatic; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - complications; Atherosclerosis - epidemiology; Atherosclerosis - immunology; Atherosclerotic cardiovascular disease (ASCVD); Autoimmune diseases; Body mass index; Cardiolipin; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - immunology; Care and treatment; Cerebral infarction; China - epidemiology; Chronic conditions; Confounding (Statistics); Diabetes; Diagnosis; Female; Glycoprotein I; Glycoproteins; Health risks; Heart attacks; Humans; Hyperlipidemia; Hypertension; Immunoglobulin G; Immunoglobulin Isotypes - blood; Immunoglobulin M; Isotypes; Lupus; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - epidemiology; Lupus Erythematosus, Systemic - immunology; Male; Medical imaging; Medical prognosis; Middle Aged; Myocardial infarction; Patients; Prevention; Prospective Studies; Quality control; Regression analysis; Review boards; Risk Factors; Systemic lupus erythematosus; Systemic lupus erythematosus (SLE); Testing; Thrombosis; China; Germany; Antiphospholipid syndrome (APS); Aspirin; Antiphospholipid antibodies (aPLs); Systemic lupus erythematosus (SLE); Atherosclerotic cardiovascular disease (ASCVD)